Distinguishing autoimmune myelofibrosis from primary myelofibrosis.
Marcellino B, El Jamal SM, Mascarenhas JO.
Clin Adv Hematol Oncol. 2018 Sep;16(9):619-626.
PMID:30256778
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A.
Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.
PMID:18988864
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A.
Am J Hematol. 2016 Dec;91(12):1262-1271. doi: 10.1002/ajh.24592.
PMID:27870387
Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.
Battukh N, Ali E, Yassin M.
Acta Biomed. 2022 Jan 19;92(6):e2021478. doi: 10.23750/abm.v92i6.12350.
PMID:35075062
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.
Griesshammer M, Al-Ali HK, Eckardt JN, Fiegl M, Göthert J, Jentsch-Ullrich K, Koschmieder S, Kvasnicka HM, Reiter A, Schmidt B, Heidel FH.
Ann Hematol. 2025 Jan;104(1):295-306. doi: 10.1007/s00277-025-06191-7. Epub 2025 Jan 31.